Dec 26 2012
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases, announced today that it has secured a $16 million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities with new mechanisms of action purposely designed for Blend’s proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together, Blend can make medicines more targeted, more effective and more tolerable.
NanoDimension led the Series B round with participation from other existing investors, Flagship Ventures and New Enterprise Associates. Proceeds from the financing will be used to expand Blend’s product and business development teams and to advance the company’s lead programs through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). The funding will enable Blend to pursue its initial focus in oncology as the company continues research and development of new classes of platinum drugs. The company will expand the development of its proprietary molecules for oncology, which include a portfolio of mono-functional platinums that have an entirely different mode of DNA platination and unprecedented biological differentiation compared to that of existing platinum drugs. Blend’s platinum drug discovery program is fueled by chemical insights provided by structural and innovative mechanistic studies of Dr. Stephen J. Lippard, who is a founder of Blend and the Arthur Amos Noyes Professor of Chemistry at the Massachusetts Institute of Technology.
“Blend has made great progress translating its novel, integrated, new molecule discovery engine and nanoparticle engineering platform into exciting first-in-class product candidates in oncology,” commented Ed Kania, Managing Partner and Chairman of Flagship Ventures. “We share the patient-focused and product-driven vision of the team at Blend, and we are excited to be joining with NanoDimension and NEA to support the Blend team with our collective resources and strategic reach as they advance their anti-cancer drug candidates.”
“This Series B investment clearly recognizes the value that the Blend team created since the last financing a year ago and will enable the company to pursue untapped opportunities with broad potential impact in oncology as we develop cancer therapies with superior selectivity and efficacy,” said Mark Iwicki, President and Chief Executive Officer of Blend Therapeutics. “With several product candidates in multi-billion dollar categories in our pipeline, this financing will allow us to advance two lead molecules through IND-enabling studies, each of which involves a novel platinum molecule with new modes of action for cancer therapy.”
Source: http://www.blendtx.com/